The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,010
Aggarwal, C., Cohen, R., Morrow, M., Kraynyak, K., Sylvester, A., Knoblock, D., Bauml, J., Weinstein, G., Lin, A., Boyer, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 124
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Chuckran, C. A., Liu, C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000967 · Cited by 147
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
Muzaffar, J., Bari, S., Kirtane, K., & Chung, C. H. (2021) · Cancers · doi:10.3390/cancers13020338 · Cited by 152
Morisada, M. V., Clavijo, P. E., Moore, E. C., Sun, L., Chamberlin, M. M., Waes, C. V., Hodge, J. W., Mitchell, J. B., Friedman, J., & Allen, C. T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395996 · Cited by 150
Xu, J., Li, Y., Fan, Q., Shu, Y., Yang, L., Cui, T., Gu, K., Tao, M., Wang, X., Cui, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28408-3 · Cited by 146
circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation
Jia, L., Wang, Y., & Wang, C. (2021) · Advanced Science · doi:10.1002/advs.202003376 · Cited by 145
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., Geest, B. G. D., Breckpot, K., Dirix, L. Y., Feldman, S. A., Criekinge, W. V., Thielemans, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 147
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 144
Self-citationLi, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 149
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Kuan, E. C., Wang, E. W., Adappa, N. D., Beswick, D. M., London, N. R., Su, S. Y., Wang, M. B., Abuzeid, W. M., Alexiev, B. A., Alt, J. A., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23262 · Cited by 150
Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer
Goel, R., Moore, W., Sumer, B. D., Khan, S. A., Sher, D. J., & Subramaniam, R. M. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18301 · Cited by 141
Gauci, M.-L., Lanoy, É., Champiat, S., Caramella, C., Ammari, S., Aspeslagh, S., Varga, A., Baldini, C., Bahleda, R., Gazzah, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0793 · Cited by 142
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 145
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 142
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 138
Hladíková, K., Koucký, V., Bouček, J., Laco, J., Grega, M., Hodek, M., Zábrodský, M., Vošmik, M., Rozkošová, K., Vošmiková, H., et al. (2019) · Journal of Immunotherapy for Cancer · doi:10.1186/s40425-019-0726-6 · Cited by 126
Prognostic role of neutrophil‐to‐lymphocyte ratio in head and neck cancer: A meta‐analysis
Takenaka, Y., Oya, R., Kitamiura, T., Ashida, N., Shimizu, K., Takemura, K., Yamamoto, Y., & Uno, A. (2017) · Head & Neck · doi:10.1002/hed.24986 · Cited by 137
Yang, W., Wong, M. C. M., Thomson, P. J., Li, K. Y., & Su, Y. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.09.016 · Cited by 136
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Ju, W., Xia, R., Zhu, D., Dou, S., Zhu, G., Dong, M., Wang, L., Sun, Q., Zhao, T., Zhou, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33080-8 · Cited by 143
Guan, X., Zhang, C., Zhao, J., Sun, G., Song, Q., & Jia, W. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.012 · Cited by 128
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133
Lechner, A., Schlößer, H., Rothschild, S. I., Thelen, M., Reuter, S., Zentis, P., Shimabukuro‐Vornhagen, A., Theurich, S., Wennhold, K., Garcia-Marquez, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17901 · Cited by 133
Kiyota, N., Hasegawa, Y., Takahashi, S., Yokota, T., Yen, C.-J., Iwae, S., Shimizu, Y., Hong, R., Goto, M., Kang, J. H., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.023 · Cited by 130
Self-citationSafety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A. S., Braña, I., Chau, N. G., Sarkar, I., Molinero, L. L., Grossman, W., Kabbinavar, F. F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy411 · Cited by 131
Self-citationHo, W. J., Yarchoan, M. M., Hopkins, A., Mehra, R., Grossman, S. A., & Kang, H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0395-x · Cited by 129
Hyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 130
Ferrarotto, R., Bell, D., Rubin, M. L., Hutcheson, K. A., Johnson, J. M., Goepfert, R. P., Phan, J., Elamin, Y. Y., Torman, D., Warneke, C. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3977 · Cited by 127
Self-citationHolistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Khabibov, M., Гарифуллин, А., Boumber, Y., Khaddour, K., Fernandez, M., Khamitov, F., Халикова, Л. В., Kuznetsova, N. S., Kit, O. I., & Kharin, L. V. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5359 · Cited by 142
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 135
O’Malley, D. M., Oaknin, A., Monk, B. J., Selle, F., Rojas, C., Gladieff, L., Berton, D., Leary, A. F., Moore, K. N., Estevez-Diz, M. D. P., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.018 · Cited by 127
Immunotherapy in advanced gastric cancer, is it the future?
Coutzac, C., Pernot, S., Chaput, N., & Zaanan, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.007 · Cited by 125
Goel, B., Tiwari, A. K., Pandey, R., Singh, A. P., Kumar, S., Sinha, A., Jain, S. K., & Khattri, A. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101426 · Cited by 136
Kidd, L. C., Chaing, S., Chipollini, J. J., Giuliano, A. R., Spiess, P. E., & Sharma, P. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.06.27 · Cited by 125
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 129
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 130
Hewavisenti, R., Arena, J., Ahlenstiel, C., & Sasson, S. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112513 · Cited by 143
Hartner, L. P. (2017) · Dental Clinics of North America · doi:10.1016/j.cden.2017.08.006 · Cited by 124
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 124
Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism
Zhu, J., Petit, P.-F., & den Eynde, B. J. V. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2269-y · Cited by 127
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Chen, R. Q., Liu, F., Qiu, X. Y., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01503 · Cited by 123
Adkins, D. R., Ley, J. C., Neupane, P. C., Worden, F. P., Sacco, A. G., Palka, K. A., Grilley‐Olson, J. E., Maggiore, R. J., Salama, N. N., Trinkaus, K. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30405-x · Cited by 122
Self-citationRitchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
Immune Checkpoint Inhibition in Head and Neck Cancer
Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 123
Tahara, M., Okano, S., Enokida, T., Ueda, Y., Fujisawa, T., Shinozaki, T., Tomioka, T., Okano, W., Biel, M. A., Ishida, K., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01960-6 · Cited by 122
Self-citationYang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 124
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
Hamoir, M., Schmitz, S., Suarez, C. M., Strojan, P., Hutcheson, K. A., Rodrigo, J. P., Mendenhall, W. M., Simó, R., Saba, N. F., Dcruz, A. K., et al. (2018) · Cancers · doi:10.3390/cancers10080267 · Cited by 120
Self-citationImmune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
D'Cruz, A., Vaish, R., & Dhar, H. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.10.013 · Cited by 103
Linxweiler, M., Kuo, F., Katabi, N., Lee, M., Nadeem, Z., Dalin, M. G., Makarov, V., Chowell, D., Doğan, S., Ganly, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3758 · Cited by 116
Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01173-w · Cited by 119
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes
Nagasaki, J., Inozume, T., Sax, N., Ariyasu, R., Ishikawa, M., Yamashita, K., Kawazu, M., Ueno, T., Irie, T., Tanji, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110331 · Cited by 126
Hu, S., Lu, H., Xie, W., Wang, D., Shan, Z., Xing, X., Wang, X.-M., Fang, J., Dong, W., Dai, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157649 · Cited by 129
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 119
Epigenetics in oral squamous cell carcinoma
Hema, K., Smitha, T. V., Sheethal, H., & Mirnalini, S. (2017) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_150_17 · Cited by 125
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0282-x · Cited by 120
Liu, Z., McMichael, E. L., Shayan, G., Li, J., Chen, K. C., Srivastava, R. M., Kane, L., Lu, B., & Ferris, R. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1350 · Cited by 121
Self-citationGeorge, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma
Cheng, Y., Li, S., Gao, L., Zhi, K., & Ren, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.761379 · Cited by 130
Zandberg, D. P., Menk, A. V., Velez, M., Normolle, D., DePeaux, K., Liu, A., Ferris, R. L., & Delgoffe, G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002088 · Cited by 119
Self-citationLi, Z., Zheng, Z., Wei, Z.-H., Zhang, L., Li, F., Lin, L., Liu, R., Huang, X., Lv, J., Chen, F., et al. (2019) · Theranostics · doi:10.7150/thno.36585 · Cited by 114
de la Iglesia, J. V., Slebos, R. J. C., Martin‐Gomez, L., Wang, X., Teer, J. K., Tan, A. C., Gerke, T. A., Aden-Buie, G., van Veen, T., Masannat, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1769 · Cited by 120
Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124
Brooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 110
Wu, D., Li, Y., Xu, P., Fang, Q., Cao, F., Lin, H., Li, Y., Su, Y., Lu, L., Chen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46444-z · Cited by 124
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
Ferris, R. L., Saba, N. F., Gitlitz, B. J., Haddad, R. I., Sukari, A. W., Neupane, P. C., Morris, J. C., Misiukiewicz, K. J., Bauman, J. E., Fenton, M. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1888 · Cited by 113
Self-citationProgress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
Harrington, K. J., Kong, A. H., Mach, N., Chesney, J. A., Fernández, B. C., Rischin, D., Cohen, E. E. W., Radcliffe, H.-S., Gümüşçü, B., Cheng, J. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1170 · Cited by 114
Self-citationKikuchi, M., Clump, D. A., Srivastava, R. M., Sun, L., Zeng, D., Díaz-Pérez, J. A., Anderson, C. J., Edwards, W. B., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1329071 · Cited by 111
Self-citationThe sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Reck, M., Taylor, F. C., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H. B., Orsini, L. S., & Gralla, R. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.029 · Cited by 111
Hellmann, M. D., Bivi, N., Calderón, B., Shimizu, T., Delafontaine, B., Liu, Z. T., Szpurka, A. M., Copeland, V., Hodi, F. S., Rottey, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3716 · Cited by 112
Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies
Lorini, L., Bescós, C., Thavaraj, S., Müller-Richter, U. D. A., Alberola‐Ferranti, M., Romero, J. P., Sáez‐Barba, M., García‐Cuenca, A. D. P., Braña, I., Bossi, P., et al. (2021) · Cancers · doi:10.3390/cancers13153696 · Cited by 111
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer
Masarwy, R., Kampel, L., Horowitz, G., Gutfeld, O., & Muhanna, N. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.2191 · Cited by 115
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Wang, Y., Du, J., Gao, Z., Sun, H., Mei, M., Wang, Y., Ren, Y., & Zhou, X. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02084-y · Cited by 118
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 112
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 113
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 111
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Qiao, X., Jiang, J. D., Pang, X., Huang, M.-C., Tang, Y.-J., Liang, X., & Tang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01721 · Cited by 119
SEOM clinical guidelines for the treatment of head and neck cancer (2020)
Mesı́a, R., Iglesias, L., Lambea, J., Martínez‐Trufero, J., Soria, A., Taberna, M., Trigo, J. M., Chaves, M., García‐Castaño, A., & Cruz, J. J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02533-1 · Cited by 110
Hanna, G. J., O’Neill, A., Shin, K., Wong, K. S., Jo, V. Y., Quinn, C. T., Cutler, J. M., Flynn, M., Lizotte, P. H., Annino, D. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2635 · Cited by 109
Self-citationStatin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Kansal, V., Burnham, A. J., Kinney, B. L. C., Saba, N. F., Paulos, C. M., Lesinski, G. B., Buchwald, Z. S., & Schmitt, N. C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005940 · Cited by 109
Self-citationMechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 113
Feng, Y., Wang, X., Bajaj, G., Agrawal, S., Bello, A., Lestini, B. J., Finckenstein, F. G., Park, J.-S., & Roy, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2842 · Cited by 109
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy
Mathew, M., Zade, M., Mezghani, N., Patel, R. D., Wang, Y., & Momen‐Heravi, F. (2020) · Cancers · doi:10.3390/cancers12102825 · Cited by 111
Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Wang, G., Zhang, M., Cheng, M., Wang, X., Li, K., Chen, J., Chen, Z., Chen, S., Chen, J., Xiong, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.009 · Cited by 113
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Yin, S., Chen, Z., Chen, D., & Yan, D. (2023) · Theranostics · doi:10.7150/thno.80091 · Cited by 115
Wang, L.-W., Liu, Y.-W. H., Chou, F., & Jiang, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0295-y · Cited by 107
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 112
Kulasinghe, A., Kapeleris, J., Kimberley, R., Mattarollo, S. R., Thompson, E. W., Thiery, J. P., Kenny, L., O'Byrne, K. J., & Punyadeera, C. (2018) · Cancer Medicine · doi:10.1002/cam4.1832 · Cited by 107
Hou, Y., Chao, Y., Hsieh, M.-H., Tung, H., Wang, H., & Shan, Y. (2019) · Cancers · doi:10.3390/cancers11040541 · Cited by 109
Cao, Z., Zhu, J., Wang, Z., Peng, Y., & Zeng, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-76798-9 · Cited by 111
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
